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Abstract
Introduction MBD2, the gene encoding methyl-CpG-binding
domain (MBD)2, is a major methylation related gene and
functions as a transcriptional repressor that can specifically bind
to the methylated regions of other genes. MBD2 may also
mediate gene activation because of its potential DNA
demethylase activity. The present case-control study
investigated associations between two single nucleotide
polymorphisms (SNPs) in the MBD2 gene and breast cancer
risk.
Methods DNA samples from 393 Caucasian patients with
breast cancer (cases) and 436 matched control individuals,
collected in a recently completed breast cancer case–control
study conducted in Connecticut, were included in the study.
Because no coding SNPs were found in the MBD2 gene, one
SNP in the noncoding exon (rs1259938) and another in the
intron 3 (rs609791) were genotyped. Odds ratios (ORs) with
95% confidence intervals (CIs) were calculated to estimate
cancer risk associated with the variant genotypes and the
reconstructed haplotypes.
Results The variant genotypes at both SNP loci were
significantly associated with reduced risk among
premenopausal women (OR = 0.41 for rs1259938; OR = 0.54
for rs609791). Further haplotype analyses showed that the two
rare haplotypes (A-C and A-G) were significantly associated
with reduced breast cancer risk (OR = 0.40, 95% CI = 0.20–
0.83 for A-C; OR = 0.47, 95% CI = 0.26–0.84 for A-G) in
premenopausal women. No significant associations were
detected in the postmenopausal women and the whole
population.
Conclusion Our results demonstrate a role for the MBD2 gene
in breast carcinogenesis in premenopausal women. These
findings suggest that genetic variations in methylation related
genes may potentially serve as a biomarker in risk estimates for
breast cancer.
Introduction
It has recently been recognized that cancer is a manifestation
of both abnormal genetic and epigenetic events [1]. Dysregu-
lated epigenetic controls, which usually are represented by
abnormal DNA methylation patterns such as global hypometh-
ylation and region specific hypermethylation, are a hallmark of
most cancers. Although the precise mechanisms underlying
methylation alterations are far from being fully understood, the
overall methylation process is mainly regulated by several
groups of regulatory proteins [2-4].
The methyl-CpG-binding domain (MBD) proteins are among
these protein families that bind specifically to a methylated
gene and mediate transcriptional repression via effects on
chromatin structure. Thus far, five MBD genes have been iden-
tified in mammalian cells that encode putative MBDs, namely
MeCP2, MBD1, MBD2, MBD3, and MBD4 [5-7]. Human
MBD genes are considered housekeeping genes because
they are widely expressed in somatic tissues [6]. Given the
epigenetic role of MBD proteins in regulating gene expression,
MBDs may be involved in cancer development by affecting the
expression of cancer related genes. In fact, there is growing
evidence that aberrant expression of MBD proteins is associ-
ated with human cancers [8,9].
The MBD2 gene is mapped to the conserved region within
human chromosome 18q21 [10]. Genomic sequence analysis
determined that the MBD2 gene contains six exons and oneR745
bp = base pairs; CI = confidence interval; MBD = methyl-CpG-binding domain; OR = odds ratio; PCR = polymerase chain reaction; SNP = single 
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R746noncoding exon spanning more than 50 kb in the genome. The
MBD2 gene encodes two potential forms of protein MBD2
that correspond to the initiation of translation starting at either
the first (MBD2a; 43.5 kDa) or second (MBD2b; 29.1 kDa)
methionine codons. The signal functions of MBD2 are to bind
specifically to methylated gene promoters and recruit histone
deacetylases and chromatin remodeling proteins. The altered
chromatin structure resulting from the binding of these factors
may be resistant to the transcriptional machinery and, as a
result, repress gene expression [11,12]. A recent finding also
suggests that MBD2 has potential DNA demethylase activity
[13], implying that it might mediate gene activation in addition
to transcriptional repression. However, two subsequent stud-
ies could not demonstrate any demethylase activity of MBD2
[14,15], and this inconsistency in the functions of MBD2
remains to be resolved.
Although our understanding of the exact function of MBD2 in
epigenetics is still in its early stages, several studies in human
cancer research have demonstrated that the MBD2 protein
plays a role in tumorigenesis. For example, a recent study [16]
showed that breast carcinomas exhibit alterations in MBD2
expression. One interesting finding from that study was that
breast carcinomas can be divided into two groups, with one
expressing very high levels of MBD2 and the other expressing
a much lower level. MBD2 has also been reported to be
involved in the repression of GSTP1 transcription in breast
cancer cells [17]. Moreover, a significant reduction in MBD2
mRNA expression was found in human colorectal and gastric
cancerous tissues [18] and peripheral blood lymphocytes [19]
in bladder cancer patients, implying a protective role for MBD2
in tumorigenesis. MBD2 protein expression and its demethyl-
ase activity were detected in normal human prostate tissue but
not in cancerous tissue [20]. These differences between types
of cancers in the abundance of MBD2 levels may reflect differ-
ent roles for MBD2 either in transcriptional repression or in the
demethylation process.
Given that there is a potential role for MBD2 in tumorigenesis,
we hypothesized that genetic polymorphisms in the MBD2
gene may modify an individual's susceptibility to human can-
cers. In this molecular epidemiologic study, we genotyped two
single nucleotide polymorphisms (SNPs; rs1259938 and
rs609791) in the MBD2 gene to investigate whether genetic
variations in the MBD2 gene are associated with breast can-




This study was built upon a recently completed breast cancer
case–control study that was undertaken in Connecticut, USA.
Detailed information regarding the study population is pro-
vided elsewhere [21]. Briefly, a total of 475 histologically con-
firmed incident breast cancer cases (ICD-O, 174.0–174.9)
and 502 randomly selected control individuals were identified
from the Tolland and New Haven County area of Connecticut
between 1 January 1994 and 31 December 1997. All of the
cases and controls were in the age range 30–80 years and
had no previous diagnosis of cancer with the exception of non-
melanoma skin cancer.
For New Haven County, eligible cases were identified from the
major hospital of the county (Yale–New Haven Hospital)
through the computer database system at the Department of
Surgical Pathology. Controls were also randomly selected
from the computer database system from among women who
were histologically confirmed to be without breast cancer. The
participation rates were 77% for cases and 71% for controls
in New Haven County. For Tolland County, because there was
no major county hospital in this county, newly diagnosed
breast cancer cases were identified from area hospital records
by the Rapid Case Ascertainment system at the Yale Compre-
hensive Cancer Center. Controls from Tolland Country were
recruited through random digit dialing methods for those
under age 65 years and randomly selected from Health Care
Financing Administration files for those aged 65 years and
over. The participation rates were 74% for cases and 64% for
controls in Tolland County.
The study pathologist reviewed all of the pathologic diagnoses
for breast cancer patients and benign breast disease controls.
Breast carcinoma were classified as carcinoma in situ, inva-
sive ductal, or lobular carcinoma, and were staged according
to the American Joint Committee on Cancer staging system
[22].
Data collection
Informed consent was obtained from all study participants
before collection of epidemiologic data through personal inter-
view. The 45-min in-person interview, completed by all study
participants, was administered by trained interviewers follow-
ing institutional guidelines for human subjects. Data on smok-
ing habits, alcohol consumption, and hormone replacement
therapy of case and control individuals was obtained. Other
information, including menstrual and reproductive factors (age
at menarche, age at first pregnancy, age at menopause, parity,
lifetime lactation history), family breast cancer history, lifetime
occupational history, body mass index, hair dye use, and resi-
dence history, was also collected. Dietary information was
obtained using a scannable semiquantitative food frequency
questionnaire developed by the Fred Hutchinson Cancer
Research Center, designed to optimize estimation of fat
intake. Menopausal status was assessed at the time of diag-
nosis. Women with hysterectomy or bilateral oophorectomy
were considered to be postmenopausal women, whereas very
few women with dubious menopausal status were considered
to represent missing data. At the completion of the interview,
blood was drawn for DNA isolation and subsequent molecular
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cealed before they were handed to laboratory personnel.
Single nucleotide polymorphism selection
A SNP search using the National Center for Biotechnology
Information SNP database [23] showed no non-synonymous
SNPs in the coding region of the MBD2 gene. Therefore, two
noncoding SNPs were chosen for genotyping. One
(rs1259938) is located in the noncoding exon and another
(rs609791) is located in intron 3 of the MBD2 gene. The non-
coding exon is generally found at the 3'-untranslated region of
a gene and this is now widely acknowledged. There is increas-
ing evidence indicating that the 3'-untranslated region of a
gene plays a vital biologic role in many post-transcriptional
regulatory pathways that control mRNA localization, stability,
and translation efficiency [24].
Genotyping methods
The restrictional fragment length polymorphism PCR assay
was used to determine the genotypes of SNP rs1259938. The
genomic DNA used for the assay was extracted from periph-
eral blood lymphocytes. The PCR primers used for amplifying
this polymorphism were as follows: forward 5'-CCTTGCCT-
GTGACTTGGACT-3' and reverse 5'-TCGCGAGTT-
TCAACAGAAAA-3'. Standard PCR was performed in a 25 µl
volume with annealing temperature at 58°C and followed by
an overnight digestion with XbaI (New England BioLabs, Bev-
erly, MA, USA) at 37°C. The products were separated for 45
min at 220 V on a 4% agarose gel stained with ethidium bro-
mide. Following electrophoresis, the homozygous G/G alleles
were represented by a DNA band with size at 319 bp,
whereas the homozygous A/A alleles were represented by
DNA bands with sizes at 103 bp and 216 bp, and the hetero-
zygotes displayed a combination of both alleles (103 bp, 216
bp and 319 bp).
The TaqMan Assay was used to determine the genotypes of
SNP rs609791. Assays-on-Demand primers and probes
(C_3079439_10; Applied Biosystems, Inc., Foster City, CA,
USA) were mixed with PCR reagents following the manufac-
turer's instructions in the TaqMan assay. Plates were sealed
and cycled at 95°C for 5 min, followed by 45 cycles at 92°C
for 15 seconds, and 60°C for 1 min in a Stratagene Real-Time
Mx3000 thermocycler (Stratagene Corp., La Jolla, CA, USA).
Each genotyping plate contained positive and negative con-
trols. Approximately 5% of the samples were duplicated to
ensure quality control in genotyping and two reviewers sepa-
rately performed genotype scoring to confirm results.
Statistical analysis
Because more than 90% of the study participants were Cau-
casians, with about 6% being black, 1% Asian, and 2% other
races, we restricted our analysis to Caucasians only (393
cases and 436 controls). Pearson's χ2 test was used to evalu-
ate differences in the distribution of selected characteristics
between cases and controls. Genotype frequencies at both
SNP loci in the control population were first checked for com-
pliance with Hardy–Weinberg equilibrium using STATA statis-
tical software (StataCorp, LP, College Station, TX, USA).
Haplotype estimation was calculated using the PHASE pro-
gram, which reconstructs haplotypes from population geno-
typing data [25]. The best haplotypes estimated by the
PHASE were assigned to each study participant. STATA was
also used to calculate both crude and adjusted odds ratios
(ORs). ORs with 95% confidence intervals (CIs) were
reported to illustrate relative cancer risk associated with gen-
otypes and haplotypes.
For a SNP genotype, study participants with homozygous
common allele were used as the reference group in OR calcu-
lation. For haplotype analysis, the most common haplotype (G-
C) was used as the reference group in risk estimation. Logistic
regression was used to control for confounding by age (as a
continuous variable), body mass index (<25 kg/m2, 25–29.99
kg/m2, >29.99 kg/m2), family history of breast cancer in first-
degree relatives, family income (tertiles based on distribution
of controls), lifetime months of breastfeeding (never, 1–5, 6–
15, >15 months) and study site (New Haven County, Tolland
County). Control of other variables (such as age at menarche,
age at menopause, number of live births) did not change the
ORs significantly, and these variables were not included in the
final model.
Results
This study, which included 393 breast cancer cases and 436
controls, was composed entirely of Caucasians. Table 1
presents the distribution of selected baseline characteristics
for cases and controls. There were significantly more post-
menopausal women in the case population (77.6%) than
among controls (66.5%), indicating an increased risk for
breast cancer associated with menopausal status. In addition,
data showed that more controls had higher family income
(31%) compared to the incidence of high family income in
breast cancer cases (23.5%). No other baseline factors exhib-
ited a material difference between cases and controls.
The genotype distributions of both SNP loci for cases and
controls (Table 2) were in Hardy–Weinberg equilibrium (χ2 =
0.35, P = 0.56 for rs1259938; χ2 = 0.31, P = 0.57 for
rs609791).
Among all women, we found no overall associations between
genotypes at these two loci and breast cancer risk after adjust-
ment for age, menopausal status, family history of breast can-
cer in first-degree relatives, family income, body mass index,
lifetime months of breastfeeding, and study site. Among pre-
menopausal women, a reduced breast cancer risk was signifi-
cantly associated with variant genotypes (homozygous minor
allele + heterozygote) at both SNP loci. Specifically, women
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Distributions of selected characteristics by case–control status in Caucasians
Variable Cases (n = 393) Controls (n = 436) P
Age at menarche (years)
<11 23 (5.9) 29 (6.7)
11–12 152 (39.2) 168 (38.6)
≥ 12 213 (54.9) 238 (54.7) 0.907
Menopausal status
Premenopausal 88 (22.4) 146 (33.5)
Postmenopausal 305 (77.6) 290 (66.5) 0.000
Age at menopause (years)
<44 76 (25.8) 91 (32.3)
44–49 105 (35.6) 87 (30.9)
≥ 49 114 (38.6) 104 (36.8) 0.202
Lifetime lactation (months)
0 242 (61.6) 260 (59.6)
1–5 50 (12.7) 61 (14.0)
6–15 56 (14.3) 59 (13.5)
≥ 15 45 (11.4) 56 (12.9) 0.853
Family history of breast cancer in first-degree relatives
Yes 94 (24.0) 98 (22.5)
No 299 (76.0) 338 (77.5) 0.623
Body mass index (kg/m2)
<25.0 72 (18.3) 77 (17.7)
25.0–29.9 100 (25.5) 110 (25.2)
≥ 30.0 221 (56.2) 249 (57.1 0.960
Fat intake
Low 120 (31.0) 141 (33.2)
Medium 132 (34.1) 143 (33.6)
High 135 (34.9) 141 (33.2) 0.786
Cigarette smoking
Never 169 (43.0) 196 (45.0)
Ever 224 (57.0) 239 (55.0) 0.534
Alcohol consumption
Never 66 (19.2) 64 (16.9)
Ever 277 (80.8) 315 (83.1) 0.411
Annual income
Low 126 (39.0) 125 (33.4)
Medium 121 (37.5) 133 (35.6)
Available online http://breast-cancer-research.com/content/7/5/R745
R749with G/A and A/A at rs1259938 had 59% reduced breast
cancer risk (OR = 0.41, 95% CI = 0.23–0.72) and women
with C/G and G/G at rs609791 had 46% reduced breast can-
cer risk (OR = 0.54, 95% CI = 0.30–0.96). However, no sig-
nificant associations were detected among postmenopausal
women.
These two SNP loci in the MBD2 gene may generate four pos-
sible haplotypes, and their frequency distributions among
cases and controls are shown in Table 3. G-C was the most
common haplotype, with a frequency of 66.90% in our control
group. The frequencies of the other three haplotypes were
5.56% (G-G), 11.70% (A-C), and 15.84% (A-G) in controls.
Among all female participants, none of these haplotypes was
associated with breast cancer risk. However, in premenopau-
sal women the two rare haplotypes halved breast cancer risk,
with ORs of 0.40 (95% CI = 0.20–0.83, P = 0.013) for A-C
and 0.47 (95% CI = 0.26–0.84, P = 0.011) for A-G. Similar
associations were not observed in postmenopausal women.
Discussion
It is becoming clear that carcinogenesis is a stepwise process
of accumulation of both genetic and epigenetic abnormalities
that can lead to cellular dysfunction. A large body of evidence
has demonstrated that the epigenetic process is involved in
breast carcinogenesis by influencing several broad gene cat-
egories, including cell cycle regulation, cell growth, steroid
receptors, tumor susceptibility, carcinogen detoxification, cell
adhesion, and inhibitors of matrix metalloproteinase genes. For
example, methylation of p16 promoter and exon 1 regions are
observed in both human breast cancer cell lines and 20–30%
of primary breast cancers [26,27]. Methylation of the promoter
region of GSTP1, a member of the glutathione S-transferases,
which are a supergene family involved in the detoxification of
carcinogens, is associated with gene inactivation in about
30% of primary breast carcinomas [28]. DNA methylation has
also been found to be an alternative mechanism of inactivation
of BRCA1 [29,30], a gene that accounts for one half of inher-
ited breast carcinomas [31]. Moreover, three members of the
steroid hormone superfamily, including estrogen receptor, pro-
gesterone receptor and retinoic acid receptor, have long been
linked to mammary carcinogenesis [32] and recent studies
have shown that epigenetic alterations appear to play a role in
silencing estrogen receptors and retinoic acid receptors in
breast malignancy [33-35]. Given the increasing evidence for
a role of the epigenetic process, especially DNA methylation,
in breast carcinogenesis, it is speculated that some genetic
variations in methylation related genes may affect the expres-
sion and function of these genes and consequently contribute
to breast cancer development.
Findings from the present study show associations between
genotypes and haplotypes of the MBD2 gene and breast can-
cer, which have not previously been examined. These results
support a potential role for methylation related genes in breast
tumorigenesis. Interestingly, MBD2 polymorphisms have dif-
ferent effects in women depending on menopausal status. Our
results demonstrate significant associations between MBD2
genotypes and haplotypes and breast cancer risk in premeno-
pausal women but not in postmenopausal women. In fact,
menopausal effects on breast cancer risk have also been
observed in a previous study investigating genetic
polymorphisms in catechol-O-methyltransferase [36]. That
study found that the low-activity allele of catechol-O-methyl-
transferase was associated with increased risk among pre-
menopausal women (OR = 2.1, 95% CI = 1.4–4.3) but was
inversely associated with postmenopausal risk (OR = 0.4,
95% CI = 0.2–0.7). Our findings support arguments from pre-
vious studies suggesting that different etiologies may be
involved in breast carcinogenesis between premenopausal
and postmenopausal women [36,37].
Although the mechanisms are not elucidated, menopausal
effects on the role of MBD2 in breast cancer development may
be related to changes in sex hormone levels. One of the
phases of breast cancer pathogenesis is exposure of breast
tissue to ovarian hormones that drive the kinetics of breast tis-
sue stem cells, resulting in carcinogenesis [38]. Dividing cells
are particularly susceptible to alterations in DNA synthesis,
DNA repair, and DNA methylation.
High 76 (23.5) 116 (31.0) 0.074
Study site
New Haven County 266 (67.7) 282 (64.7)
Tolland County 127 (32.3) 154 (35.3) 0.361
Live births
0 46 (11.95) 66 (15.46)
1–2 200 (51.95) 202 (47.31
≥ 2 139 (36.10) 159 (37.24) 0.252
Note that missing data for each characteristic were excluded from the analyses. Values are expressed as n (%).
Table 1 (Continued)
Distributions of selected characteristics by case–control status in Caucasians
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controlled by hormone receptors, the expression of which is
regulated by the methylation status of their promoter regions
[33-35].
On the other hand, steroid hormones may influence the epige-
netic blue print of methylation of certain genes and conse-
quently activate or inactivate gene expression [39]. Even
though MBD2 might be involved in the epigenetic regulation
of steroid hormone receptor gene expression, MBD2 itself
Table 2
MBD2 genotypes, menopausal status and breast cancer risk in Caucasians
MBD2 genotype Cases (n = 393) Controls (n = 436) Crude OR (95% CI) ORa (95% CI)
SNP 1 (rs1259938)
All women
G/G 210 (53.4) 226 (51.8) 1.00 1.00
G/A 158 (40.2) 179 (41.1) 0.95 (0.71–1.27) 0.94 (0.70–1.26)
A/A 25 (6.4) 31 (7.1) 0.86 (0.49–1.52) 0.86 (0.49–1.54)
G/A + A/A 183 (46.6) 210 (48.2) 0.94 (0.71–1.23) 0.94 (0.71–1.24)
Premenopausal women
G/G 59 (67.1) 69 (47.3) 1.00 1.00
G/A 25 (28.4) 65 (44.5) 0.43 (0.24–0.77) 0.40 (0.22–0.74)
A/A 4 (4.6) 12 (8.2) 0.39 (0.12–1.26) 0.39 (0.12–1.29)
G/A + A/A 29 (33.0) 77 (52.7) 0.42 (0.24–0.73) 0.41 (0.23–0.72)
Postmenopausal women
G/G 151 (49.5) 157 (54.1) 1.00 1.00
G/A 133 (43.6) 114 (39.3) 1.24 (0.88–1.74) 1.24 (0.88–1.75)
A/A 21 (6.9) 19 (6.6) 1.16 (0.59–2.27) 1.15 (0.58–2.29)
G/A + A/A 154 (50.5) 134 (45.9) 1.23 (0.90–1.70) 1.24 (0.90–1.72)
SNP 2 (rs609791)
All women
C/C 243 (63.9) 260 (61.6) 1.00 1.00
C/G 120 (31.6) 140 (33.2) 0.92 (0.68–1.24) 0.92 (0.68–1.24)
G/G 17 (4.5) 22 (5.2) 0.83 (0.43–1.59) 0.85 (0.44–1.64)
C/G + G/G 237 (36.1) 162 (38.4) 0.90 (0.68–1.21) 0.91 (0.68–1.22)
Premenopausal women
C/C 60 (70.6) 80 (56.3) 1.00 1.00
C/G 20 (23.5) 55 (38.7) 0.48 (0.26–0.89) 0.47 (0.26–0.88)
G/G 5 (5.9) 7 (5.0) 0.95 (0.29–3.15) 1.02 (0.30–3.49)
C/G + G/G 25 (29.4) 62 (43.7) 0.54 (0.30–0.95) 0.54 (0.30–0.96)
Postmenopausal women
C/C 183 (62.0) 180 (64.3) 1.00 1.00
C/G 100 (33.9) 85 (30.4) 1.16 (0.81–1.65) 1.15 (0.80–1.64)
G/G 12 (4.1) 15 (5.3) 0.79 (0.36–1.73) 0.80 (0.36–1.76)
C/G + G/G 112 (38.0) 100 (35.7) 1.10 (0.78–1.55) 1.10 (0.78–1.55)
Values are expressed as n (%). aAdjusted for age (as a continuous variable), body mass index (<25 kg/m2, 25–29.99 kg/m2, >29.99 kg/m2), 
family history of breast cancer in first-degree relatives, menopausal status, family income (tertiles based on distribution of controls), lifetime months 
of breast feeding (never, 1–5, 6–15, ≥ 15 months) and study site. CI, confidence interval; OR, odds ratio.
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MBD2 plays different roles in breast carcinogenesis when hor-
mone levels dramatically change. Our findings support this
speculation in that we found a significantly protective role of
MBD2 variants in premenopausal women but no significant
associations in postmenopausal women.
There are limitations to the present study. Only Caucasian
women were included in the study, and so hypotheses must
be further examined in multi-ethnic groups. In addition, the
sample sizes of our study limit the analyses to explore other
potential risk factors. Traditional risk factors such as parity and
family history of cancer did not differ between cases and con-
trols, which could also be due to the sample sizes. Inaccurate
recall may affect our assessment of family history of cancer as
well.
Conclusion
These findings imply a potential link between DNA methylation
processes and hormonal expression. Although large molecular
epidemiologic studies are warranted to further examine asso-
ciations between MBD2 polymorphisms and breast cancer in
multi-ethnic groups, this study suggests that genetic variations
in methylation related genes may serve as a promising biomar-
ker in risk estimate of breast cancer.
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